Relevance of ARID1A Mutations in Endometrial Carcinomas
Antonio De Leo1,2, Gloria Ravegnini3, Francesco Musiani4
1Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna-Molecular Diagnostic Unit, Azienda USL di Bologna, 40138 Bologna, Italy.
Abstract:
Since the Cancer Genome Atlas (TCGA) project identified four distinct groups based on molecular alterations, mutation analyses have been integrated into the characterization of endometrial carcinomas (ECs). ARID1A seems to be the subunit more involved in the loss of function of the SWI/SNF complex in ECs. The aim of this study is to define the relevance of ARID1A alterations in a cohort of EC, studying the possible associations between DNA mutation (genomic level), RNA expression (transcriptomic level), and protein expression (proteomic level). A total of 50 endometrial carcinomas were characterized for ARID1A mutations (using targeted DNA next-generation sequencing-NGS), ARID1A gene expression (using RNAseq and qRT-PCR), and ARID1A protein expression (using immunohistochemistry-IHC). Moreover, we have investigated if ARID1A mutations may alter the protein structure, using the Protein Data Bank sequence. We found a good correlation between ARID1A mutations and protein immunostaining, even if we did not find statistically significant differences in the ARID1A expression levels. In conclusion, our data demonstrated that the molecular characterization of ARID1A should be associated with IHC analysis, mainly in those cases harboring "novel" ARID1A mutations or in those alterations with "uncertain" pathogenic significance.
Insights
ARID1A mutations in endometrial carcinomas correlate with protein levels, aiding molecular characterization. Integrating DNA mutation analysis with immunohistochemistry is crucial for accurate diagnosis.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- The Cancer Genome Atlas identified distinct molecular groups in endometrial carcinomas (ECs).
- ARID1A alterations are frequently implicated in SWI/SNF complex loss-of-function in ECs.
Purpose of the Study:
- To assess the relevance of ARID1A alterations in ECs.
- To investigate associations between ARID1A DNA mutation, RNA expression, and protein expression.
Main Methods:
- Targeted DNA next-generation sequencing (NGS) for ARID1A mutations.
- RNA sequencing (RNAseq) and qRT-PCR for ARID1A gene expression.
- Immunohistochemistry (IHC) for ARID1A protein expression.
Main Results:
- A strong correlation was observed between ARID1A mutations and ARID1A protein immunostaining.
- No statistically significant differences in ARID1A expression levels were found.
- Analysis of ARID1A mutations' impact on protein structure was performed.
Conclusions:
- Molecular characterization of ARID1A in ECs should be combined with IHC analysis.
- This integrated approach is particularly important for novel or uncertain ARID1A mutations.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Related Concept Videos
Non-LTR Retrotransposons
Nondisjunction
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
